HQL offers a high 12% yield and trades at a discount, making it attractive for income-focused investors seeking healthcare sector exposure. The fund is heavily weighted in biotechnology, leading to ...
abrdn Life Sciences Investors Fund maintains a buy rating, offering a compelling 11.6% yield and trading at a 9.58% NAV discount. HQL’s income-focused strategy relies on net realized gains, supporting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results